NTM Lung Infection Due to MAC

Clinical trial pipeline · Data from ClinicalTrials.gov

See which NTM Lung Infection Due to MAC trials you may qualify for

Total trials

Actively recruiting

Phase 3 trials

Completed

Trial phase breakdown

Trial status

All recent trials (1 shown)

CompletedPhase 3

NCT02628600

Open-label Safety Extension Study Assessing Safety and Tolerability of LAI in Patients Who Participated in Study INS-212

This is an open-label safety extension study to assess the safety and tolerability of once daily dosing of 590 mg Liposomal Amikacin for Inhalation (LAI) added…

Location not specified163 participantsStarted 2016-02-05

Treatment: LAI 590 mg, Multi-drug regimen